Valuation: Agios Pharmaceuticals, Inc.

Market Cap 1.95B 1.71B 1.62B 1.47B 2.76B 187B 2.77B 19.33B 7.47B 95.28B 7.3B 7.14B 306B P/E 2026 *
-5.74x
P/E 2027 * -8.82x
Enterprise Value 1.69B 1.48B 1.4B 1.27B 2.39B 162B 2.4B 16.77B 6.48B 82.66B 6.33B 6.2B 266B EV / Sales 2026 *
9.25x
EV / Sales 2027 * 5.15x
Free-Float
77.8%
Yield 2026 *
-
Yield 2027 * -
1 day+2.58%
1 week+1.06%
Current month-0.77%
1 month-2.51%
3 months-11.82%
6 months+13.56%
Current year+22.78%
1 week 31.37
Extreme 31.37
35.36
1 month 31.37
Extreme 31.37
35.38
Current year 24.29
Extreme 24.29
44.09
1 year 22.24
Extreme 22.24
46
3 years 19.8
Extreme 19.795
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 07/08/2022
Director of Finance/CFO 51 25/09/2022
Chief Tech/Sci/R&D Officer 47 31/08/2021
Director TitleAgeSince
Director/Board Member 66 08/12/2014
Director/Board Member 73 22/06/2015
Director/Board Member 73 26/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
04/08/26 Sell

Chief Technology Officer

-30,000 0.0504%
08/07/26 Free

Director

2,894 0.0049%
01/07/26 Exercice

Chief Technology Officer

20,757 0.0349%
Change 5-day change 1-year change 3-year change Capi.($)
+2.58%+1.06%-14.15%+36.21% 1.95B
-0.37%+1.12%+57.21%+84.56% 72.26B
-0.07%-3.08%+37.74%+84.21% 60.24B
+0.75%+6.06%+36.71%+19.87% 27.73B
-0.14%-1.94%-14.13%+354.32% 25.73B
+0.57%+3.14%+1.02%-3.92% 24.75B
+1.10%+1.86%+25.07%-8.51% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.36%+0.02%+49.51%+163.05% 14.41B
-2.53%-1.39%-6.38%+469.36% 14.23B
Average +0.05%-0.27%+32.28%+152.23% 27.71B
Weighted average by Cap. -0.10%-1.05%+37.77%+124.66%

Financials

2026 *2027 *
Net sales 182M 160M 152M 138M 259M 17.51B 260M 1.81B 701M 8.94B 685M 670M 28.72B 351M 309M 292M 265M 497M 33.68B 500M 3.49B 1.35B 17.19B 1.32B 1.29B 55.22B
Net income -338M -297M -281M -255M -479M -32.44B -482M -3.36B -1.3B -16.56B -1.27B -1.24B -53.19B -230M -202M -191M -173M -326M -22.07B -328M -2.28B -883M -11.26B -863M -844M -36.18B
Net Debt -258M -227M -214M -194M -365M -24.73B -367M -2.56B -989M -12.62B -967M -946M -40.54B -137M -121M -114M -104M -195M -13.19B -196M -1.37B -527M -6.73B -516M -505M -21.62B
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
28/09/26 US$33.42 +2.58% 861,093
25/09/26 US$32.58 -0.97% 996,512
24/09/26 US$32.90 -3.77% 1,635,129
23/09/26 US$34.19 -2.23% 752,478
22/09/26 US$34.97 +3.00% 1,170,409
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.58USD
Average target price
46.25USD
Spread / Average Target
+41.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGIO Stock